Biotechnology stocks are not universally "bad," but they are characterized by extreme volatility, high risk, and unique market behaviors that can lead to substantial financial losses for unwary investors. The sector is heavily dependent on unpredictable binary events, such as clinical trial outcomes, regulatory decisions by agencies like the FDA, and complex patent litigations. Many biotechnology firms operate at a net loss for years while pouring massive amounts of capital into research and development before ever bringing a commercial product to market. Furthermore, regulatory hurdles, reimbursement negotiations with health authorities, and intense scientific competition mean that even promising drugs can fail unexpectedly. Consequently, while successful biotech stocks can yield extraordinary exponential gains, their inherent speculative nature requires a high risk tolerance and rigorous fundamental analysis.